AmMax Bio
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, AmMax Bio sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
AmMax Bio: 4 sponsored US clinical trials, none currently recruiting.
AmMax Bio sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignancy, with 1 trials.
Upper-quartile sponsor footprint
AmMax Bio sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
NCT05349643
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
NCT04731675
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
NCT02713529
A Study of AMG 820 in Subjects With Advanced Solid Tumors
NCT01444404
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Therapeutic Areas
How the AmMax Bio early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 4 completed (100%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Advanced Malignancy (1 trial), 5 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
AmMax Bio: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
AmMax Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this AmMax Bio page
4 registered trials is a research-attention snapshot, not an endorsement of AmMax Bio or any single study.
- None of AmMax Bio's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Advanced Malignancy is the condition AmMax Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Malignancy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. AmMax Bio pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.